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708Lower extremity arterial reconstruction for critical
limb ischemia in diabetes
Enzo Ballotta, MD, Antonio Toniato, MD, Giacomo Piatto, MD, Franco Mazzalai, MD, and
Giuseppe Da Giau, MD, Padova, Italy
Background: The impact of diabetes mellitus on the technical and clinical outcomes of infrainguinal arterial reconstruction
(IAR) for critical limb ischemia (CLI) remains controversial. This study analyzed the outcome of IAR in diabetic patients
with CLI over a 17-year period.
Methods: Details on all consecutive patients undergoing primary IAR at our institution were stored prospectively in
a vascular registry from 1995 to 2011. Demographics, risk factors, indications for surgery, inﬂow sources and outﬂow
target vessels, types of conduit, and adverse outcomes were analyzed. Postoperative surveillance included clinical exam-
ination, duplex scans, and ankle-brachial index measurements in all patients at discharge, 1 and 6 months after surgery,
and every 6 months thereafter. End points were patency, limb salvage, survival, and amputation-free survival rates, and
were assessed using Kaplan-Meier life-table analysis. The c2 or Fisher exact, Student t, and log-rank tests were used to
establish statistical signiﬁcance.
Results:Overall, 1407 IARs were performed in 1310 patients with CLI by the same surgeon, 705 (50.2%) in 643 diabetic
patients and 702 in 667 nondiabetic patients. Autogenous vein conduits were used in 87% of the IARs. There were no
perioperative deaths. Diabetic patients had signiﬁcantly more major (16.7% vs 11.8%; P[ .02) and minor complications
(9.7% vs 6.5%; P [ .02) than nondiabetic patients. At 5 and 10 years, there were no signiﬁcant differences between
diabetic and nondiabetic patients in the rates of primary patency (65% and 46% vs 69.5% and 57%; log-rank test, P[ .09),
secondary patency (76% and 60% vs 80% and 68%; log-rank test, P [ .20), limb salvage (88% and 76% vs 91% and 83%;
log-rank test, P [ .12) survival (51% and 34% vs 57% and 38%; log-rank test, P [ .41), or amputation-free survival
(45.5% and 27% vs 51% and 29%; log-rank test, P[ .19). The type of conduit did not affect patency or limb salvage rates
in either group.
Conclusions: Diabetic patients receiving IAR for CLI can have the same survival and amputation-free survival rates as
nondiabetic patients. Their comparable technical and clinical outcomes strongly demonstrate that diabetics with CLI
can expect the same quantity and quality of life as nondiabetics with CLI, and aggressive attempts at limb salvage in
patients with diabetes mellitus, including distal and foot level bypass grafting, should not be discouraged. (J Vasc Surg
2014;59:708-19.)With its rising incidence (expected to increase by
200% between 2005 and 20501), diabetes mellitus
(DM) is one of major risk factors for peripheral arterial
disease (PAD).2 Its prevalence is very high among people
with critical limb ischemia (CLI), deﬁned as pain at rest
and/or the presence of ischemic ulcer or gangrene,
ranging between 35% and 80% of patients undergoing
lower extremity bypass surgery to avoid limb loss
(opposed to around 10% in the general population),3
making the management of CLI in diabetic patients an
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://dx.doi.org/10.1016/j.jvs.2013.08.103have been reports of infrainguinal arterial reconstruction
(IAR) for CLI in diabetics being associated with higher
rates of revascularization failure, limb loss, morbidity,5-8
and mortality,6,8-12 and DM is reportedly an independent
predictor of failure in percutaneous lower extremity proce-
dures in patients with CLI, accounting for unacceptably
frequent restenoses needing reinterventions.13,14 Many
studies involving aggressive revascularization efforts and
exploiting technical advances in extreme distal arterial
reconstruction and better postoperative care have chal-
lenged these results, however, reporting excellent tech-
nical outcomes after IAR for CLI, with no difference
between diabetic and other patients.9,10,15,16-23 There is
no standard method for reporting the outcome of lower
extremity vascular reconstructions. Most studies only
measure the effectiveness and durability of IAR for CLI
in technical terms as patency and limb salvage (deﬁned
as preservation of the affected limb with no need for
major amputation),3,5,7,9-12,15,16-23 neglecting such clin-
ical parameters as amputation-free survival (deﬁned as
survival with a saved functional limb).6,8,22 While the
former are the most important objective of the surgery,
the latter would be the main goal from the patient’s point
of view. Given the conﬂicting data on the technical
outcomes and amputation and mortality risks after IAR
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going IAR for CLI fared worse than other patients.
METHODS
Patients. Details of all consecutive patients under-
going primary IAR for PAD at our tertiary referral center
between 1995 and 2011 were stored prospectively in
a vascular registry. For the purpose of the study, the
registry was queried to identify diabetic and other patients
treated up until December 2011. Type 1 and type 2 dia-
betic patients were considered as a single group because
there were no differences in their demographic and clinical
characteristics at presentation. The following data were
considered: patient demographics, risk factors, indication
for revascularization, inﬂow source and outﬂow target
vessel, type of conduit, and adverse outcomes. An electro-
cardiogram (ECG) was obtained for each patient, and any
past myocardial infarction (MI), congestive heart failure,
and/or angina were recorded. Patients who had an
uneventful clinical history and normal ECG results under-
went no further work-up; for the other cases, our consul-
tant cardiologist decided whether echocardiograms and/or
dipyridamole thallium scans were warranted. All patients
underwent preoperative standard biplanar arteriography,
magnetic resonance angiography, or computed tomog-
raphy angiography, or a combination thereof, to conﬁrm
the clinical and vascular laboratory diagnosis of PAD (based
on arterial mapping with duplex ultrasonography and
measuring the ankle-brachial index [ABI]) and plan sur-
gery. All patients with foot lesions were treated on the basis
of a standard protocol.24
Surgical technique. All revascularizations were com-
pleted using a single-team approach for arterial dissection
and vein harvesting when an autologous vein was used.
The preferred conduit was the great saphenous vein (SV),
which was harvested whenever feasibledjudging from
venous mapping by duplex scan and conﬁrmed to be
appropriate when examined directly during surgerydand
the reversed SV bypass was the surgeon’s personally
preferred procedure. If the ipsi- or contralateral great SV
was unsuitable or not totally available, and spliced veins
(great/small SV and arm vein) were unavailable, then the
surgeon opted for a 7- or 8-mm polytetraﬂuoroethylene
(PTFE) graft (thin-walled expanded PTFE [Gore-Tex;
W. L. Gore, Flagstaff, Ariz]) instead. If the surgeon was
able to conﬁrm preoperative angiographic ﬁndings of the
superﬁcial femoral artery or the popliteal artery sufﬁcing for
inﬂow, then a short bypass revascularization was per-
formed, exposing the chosen inﬂow artery in the usual way.
All distal anastomotic sites below the knee underwent
standard vein patch angioplasty no longer than 3 cm, as
described elsewhere.25 The vein for the patch was obtained
from wherever one was available (eg, saphenous remnants,
veins harvested from an arm under local anesthesia, or SV
collaterals). Revascularization was always completed with
patients under regional anesthesia (epidural or spinal) and
administering intravenous unfractionated heparin (5000
U) before clamping; heparin was not reversed withprotamine. Intraoperative contrast or duplex scan arteri-
ography was not used. Heparin infusion is started 6 to 10
hours postoperatively, with oral warfarin administered on
the ﬁrst postoperative day, regardless of the conduit used.
Warfarin treatment was then continued for 6 months,
aiming to achieve a normalized ratio of two to three in
most cases; aspirin (100 mg a day) was prescribed when
warfarin was withdrawn. After 6 months, 100-mg aspirin
was taken daily. Patients who are already taking statins,
beta-blockers, or angiotensin-converting enzyme inhibi-
tors, or on a diet rich in omega-3 fatty acids continued to
take their treatment during the postoperative period.
Perioperative cardiac complications were classiﬁed by
the consultant cardiologist and included (1)MI with a diag-
nosis based on creatine kinase levels and ECG ﬁndings;
(2) pulmonary edema conﬁrmed by chest radiography;
(3) documented ventricular ﬁbrillation or primary cardiac
arrest; and (4) new congestive heart failure requiring a pace-
maker. A postoperative ECG was routinely obtained in all
patients with a history of coronary artery disease, conges-
tive heart failure, or arrhythmia (rhythm other than sinus),
and cardiac isoenzymes were obtained in all patients who
had new ﬁndings at postoperative ECG.
Postoperative surveillance. All patients had a clinical
examination with duplex scans and their ABI measured at
the time of discharge, then at 1 and 6 months after surgery,
and every 6 months afterward. A color duplex scan of the
inﬂow artery, the entire conduit, both anastomoses, and
the initial portion of the outﬂow artery was always per-
formed as part of their follow-up. A palpable distal pulse,
the ABI, or a patent graft on duplex scan was used to judge
the patency of the graft. When any stenoses were discov-
ered on duplex scanning, arteriography or computed
tomography angiography were used to conﬁrm the ﬁnding,
and they were repaired electively when imaging indicated
a more than 50% reduction in diameter.
After surgery, patients were examined as often as neces-
sary until their wounds had healed completely, and this
process was recorded in terms of any wound-related
complications that prompted readmission to hospital,
redo surgery, or extra treatments (antibiotics or a nurse’s
visiting at home), as well as the time taken for surgical inci-
sions and ischemic wounds requiring arterial reconstruction
to heal. Secondary procedures needed to treat ischemic
ulcers or gangrene (eg, debridement or toe amputation)
were also included in calculating the total time taken for
ischemic wounds to heal. If the complete treatment of
the original ischemic lesions also involved minor toe or
foot amputations or debridement after the arterial recon-
struction, they were seen as forming part of the primary
procedure, not as redo surgery. The criteria adopted in
our analysis were chosen so as to comply with the standards
of the Ad Hoc Committee of the Joint Council of Vascular
Societies for Reports Dealing with Lower Extremity
Ischemia.26
Statistical analysis. Continuous data were compared
with Student t-test, frequencies and categorical data with
the c2 or Fisher exact test, as appropriate. Primary patency
Table I. Demographics, risk factors, comorbidities, and clinical presentation
Total DM nDM P value
Lower extremity revascularizations 1407 (100) 705 (50.2) 702 (49.8)
Patients 1310 (100) 643 (49.0) 667 (51.0)
Male 833 (63.6) 418 (65.0) 415 (62.2) .29
Age, years 72.9 6 9.8 75.7 6 6.9 <.001
Hyperlipemiaa 794 (60.6) 411 (63.9) 383 (57.4) .01
Hypertensionb 858 (65.5) 439 (68.3) 419 (62.8) .03
Smoking historyc 709 (54.1) 358 (55.7) 351 (52.6) .27
CKD (creatinine >2.0 mg/dL) 146 (11.1) 85 (13.2) 61 (9.1) .02
Cardiac disease 677 (51.6) 354 (55.0) 323 (48.4) .01
Prior MI 365 (27.9) 180 (28.0) 185 (27.7) .91
Prior PTA stenting/CABG 255 (19.5) 129 (20.0) 126 (18.9) .59
Prior inﬂow procedures 208 (15.8) 103 (16.0) 105 (15.7) .89
History
Pulmonary disease 219 (16.7) 111 (17.2) 108 (16.2) .60
Stroke 143 (10.9) 76 (11.8) 67 (10.0) .30
Clinical presentation
Rest pain 359 (25.5) 138 (19.6) 221 (31.5) <.001
Nonhealing ulcer 535 (38.0) 289 (41.0) 246 (35.0) .02
Gangrene 513 (36.5) 278 (39.4) 235 (33.5) .02
ABI measurement 0.51 6 0.36 (0.32-0.55) 0.43 6 0.24 (0.36-0.46) <.001
ABI, Ankle-brachial index; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; DM, diabetes mellitus; MI, myocardial infarction; nDM, no
diabetes mellitus; PTA, percutaneous transluminal angioplasty; SD, standard deviation.
Continuous data are presented as mean ± standard deviation (range) and categoric data as number (%).
aArterial pressure >160/90 mm Hg or blood pressure treated with medication.
bSerum concentration of cholesterol >6.5 mmol/L or triglycerides >2.0 mmol/L.
cCurrent use or cessation within the last 5 years.
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intervention); assisted primary patency (patency supported
by simple measures, primarily percutaneous transluminal
angioplasty [PTA], or patch angioplasty); secondary
patency (patency of the thrombosed original graft kept
patent by thrombectomy, thrombolytic therapy, PTA,
patch angioplasty, and proximal/distal graft extension);
limb salvage; amputation-free survival; and survival rates
were calculated using the actuarial life-table method
(Kaplan-Meier analysis), and curves were compared using
the Mantel-Cox log-rank test. Cox proportional hazard
analysis was used to see which statistically or marginally
signiﬁcant factors at univariate analysis could inﬂuence
outcomes, calculating the odds ratio with 95% conﬁdence
intervals. All tests were two-tailed and statistical signiﬁ-
cance was inferred at a P value of less than .05. Since each
perioperative and late outcome was correlated with the
surgical procedure, and patients undergoing bilateral IAR
were exposed to twice the risk of graft failure or limb loss,
several items of data were analyzed vis-à-vis surgical pro-
cedures instead of patients.
RESULTS
During the study period, 1407 IARs were performed
for CLI in 1310 patients by the same surgeon at our
center; 643 patients (48%; 705 IARs) were diabetic and
667 (702 IARs) were not. Staged bilateral IARs were per-
formed in 97 patients (62 of them diabetic). Another 181
patients underwent 215 IARs (34 bilateral) for claudication
and were not considered for this analysis. Arterial recon-
structive surgery was not considered for 54 other patientswho were mentally impaired (n ¼ 37) or had a life expec-
tancy of less than 1 year (n ¼ 17) and who were bedridden
or nonambulatory, and 87 (68 of them diabetic) with
extensive ischemic soft tissue breakdown between the
calcaneus and metatarsal heads (plantar region). All the
54 former patients had necrotic ulcers or gangrene; primary
amputations were needed to treat their disease in 33 cases,
whereas the other 21 had major amputations, which were
usually performed no more than a month after percuta-
neous procedures had proven ineffectual. Among the latter
87 patients with extensive tissue loss in the plantar region,
48 underwent early major amputation (within 30 days),
whereas in 39, it was delayed after a primary percutaneous
intervention had failed. The patients referred for primary
amputation at our institution formed a different cohort
with no scope revascularization or ultimate ambulation,
and they were transferred to general surgery or orthopedic
units. Table I summarizes the demographics, risk factors,
comorbidities, and other variables for the diabetic and
nondiabetic patients considered here; the former were
signiﬁcantly younger at presentation (72.9 6 9.8 vs
75.7 6 6.9; P < .001) and more likely to have arterial
hypertension (68.3% vs 62.8%; P ¼ .03), cardiac disease
(55.0% vs 48.4%; P ¼ .01), hyperlipidemia (63.9% vs
57.4%; P ¼ .01), and chronic kidney disease (CKD;
13.2% vs 9.1%; P ¼ .02). Patients who had previously
undergone more proximal endovascular procedures (PTA
alone or PTA and stenting of the iliac artery) to improve
inﬂow in the ipsilateral limb were comparable in the two
groups. The two groups did not differ in any of the other
variables considered (Table I). The indications for surgery
Table II. Inﬂow sources, outﬂow target vessel, type of conduit, and preoperative foot care procedures
Variable Total, No. (%) DM, No. (%) nDM, No. (%) P value
Inﬂow sources
Iliac/graft 195 (13.8) 90 (12.8) 105 (14.9) .23
CFA 714 (50.7) 367 (52.0) 347 (49.4) .32
DFA 75 (5.3) 32 (4.5) 43 (6.1) .18
Distal SFA/AK popliteal 260 (18.5) 139 (19.7) 121 (17.2) .24
BK popliteal 111 (7.9) 57 (8.0) 54 (7.7) .78
TPT/tibial 52 (3.7) 20 (2.8) 32 (4.5) .09
Outﬂow vessel target
AK popliteal 364 (25.9) 161 (22.8) 203 (28.9) .009
BK popliteal/TPT 358 (25.4) 167 (23.7) 191 (27.2) .13
Tibial 515 (36.6) 279 (39.6) 236 (33.6) .02
Proximal third 196 (13.9) 102 (14.5) 94 (13.4) .56
Mid-third 88 (6.2) 48 (6.8) 40 (5.7) .39
Distal third 231 (16.4) 129 (18.2) 102 (14.5) .06
Inframalleolar artery 170 (12.1) 98 (13.9) 72 (10.2) .03
Bypass procedure conduit
Reversed autogenous GSV 1118 (79.4) 569 (80.7) 549 (78.2) .24
In situ 27 (1.9) 12 (1.7) 15 (2.1) .55
Spliced vein (GSV, SSV, arm) 40 (2.8) 17 (2.4) 23(3.2) .32
Composite (vein/PTFE) 48 (3.4) 26 (3.7) 22 (3.1) .56
PTFE 174 (12.4) 81 (11.5) 93 (13.2) .31
Preoperative foot care procedures
Drainage 170 (12.1) 99 (14.0) 71 (10.1) .02
Debridement 215 (15.3) 124 (17.6) 91 (12.9) .01
AK, Above-the-knee; BK, below-the-knee; CFA, common femoral artery; DFA, deep femoral artery; DM, diabetes mellitus; GSV, great saphenous vein; nDM,
no diabetes mellitus; PTFE, polytetraﬂuoroethylene; SFA, superﬁcial femoral artery; SSV, small saphenous vein; TPT, tibial-peroneal trunk.
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common among the diabetics in the subset of nonhealing
ulcer (41% vs 35%; P ¼ .02) or gangrene (39.4% vs 33.5%;
P ¼ .02), whereas rest pain was signiﬁcantly more
common in nondiabetics (31.5% vs 19.6%; P < .001). In
both groups, the most frequent inﬂow sources were the
common femoral artery and the superﬁcial femoral artery
or above-the-knee popliteal artery (52% and 19.7% in dia-
betics, 49.4% and 17.2% in nondiabetics, respectively),
whereas tibial and inframalleolar arteries were used as
target outﬂow vessels in more than one-half of the diabetic
group, reﬂecting the different patterns of disease in both
groups (Table II). The reversed autogenous great SV
was used for most revascularizations (81% in the diabetic
group and 78% in the other group); there was no differ-
ence between the groups in the use of in situ or spliced
veins or composite or prosthetic conduits (Table II).
Preoperative foot care procedures (ie, drainage or debride-
ment) were needed in signiﬁcantly more diabetic patients
(14% vs 10%; P ¼ .02; and 17.6% vs 12.9%; P ¼ .01,
respectively).
Perioperative mortality and morbidity data.
Table III details the perioperative outcomes. There were
no perioperative deaths. Diabetic patients had a signiﬁ-
cantly higher incidence of major (16.7% vs 11.8%; P ¼ .02)
and minor complications (9.7% vs 6.5%; P ¼ .02), but the
differences failed to reach signiﬁcance when each systemic
or local complication was considered separately. Fifty-seven
grafts failed and/or required revision within the ﬁrst
30 days following the initial operation (32 in the diabetic
group and 25 in the nondiabetic group) because of graftthrombosis. Eight of the thrombosed grafts were not
revised owing to a poor target vessel (n ¼ 6) or patients’
refusal (n ¼ 2), and 17 of the revised grafts thrombosed
again in the perioperative period, resulting in 25 major
amputations (Table III). Flow was restored and maintained
in 32 grafts. An additional 33 grafts (14 in the diabetic
group and 19 in the nondiabetic group) were identiﬁed as
being at high risk for failure using duplex ultrasonography
in the immediate postoperative period; operative revision
was performed for 19 grafts, PTA was used in 9, and 5 were
treated with a combination of PTA and operative revision.
The diabetic group had more additional local procedures
(26.5% vs 12.9%; P < .001) and minor amputations (27.5%
vs 22.5%; P ¼ .03), whereas no differences emerged
between the two groups in terms of the improvement in
postoperative ABI measurements.
Long-term outcomes. Of the 1310 patients alive
30 days after IAR, 42 (3.2%, 42 IARs) were lost to
follow-up, so 1268 patients (96.8%, 1365 IARs)
completed the follow-up, and 625 of them (687 IARs)
were diabetic. The median follow-up was 6.3 years in the
diabetic group (mean, 7 6 2.2; range, 0.1-17 years) and
7.1 years in the other group (mean, 7.8 6 2.6; range,
0.1-17 years). The two groups were stratiﬁed by vein or
prosthetic graft to establish whether this might inﬂuence
the technical outcome. Figs 1-6 show details of Kaplan-
Meier life-table analyses on primary patency, assisted
primary patency, secondary patency, limb salvage, survival,
and amputation-free survival rates for the diabetic and
nondiabetic groups, before and after stratifying patients by
type of conduit.
Table III. Perioperative (30-day) outcomes
Total DM nDM P value
Death 0
Systemic complications 205 (14.6) 118 (16.7) 87 (11.6) .02
Nonfatal MI 39 (2.8) 24 (3.4) 15 (2.1) .14
Renal failure 29 (2.0) 17 (2.4) 12 (1.7) .35
Pneumonia 53 (3.8) 30 (4.2) 23 (3.2) .33
Arrhythmia 84 (6.0) 47 (6.7) 37 (5.2) .27
Graft thrombosis 57 (4.0) 25 (3.5) 32 (4.5) .33
Vein 21 (1.5) 9 (1.3) 12 (1.7) .50
PTFE 36 (2.5) 16 (2.2) 20 (2.8) .49
Major amputation 25 (1.8) 17 (2.5) 8 (1.3) .07
Minor complications 115 (8.1) 69 (9.7) 46 (6.5) .02
Wound hematoma/dehiscence 45 (3.2) 27 (3.8) 18 (2.5) .17
Inguinal lymphocele 62 (4.4) 36 (5.1) 26 (3.7) .20
Wound infection 8 (0.5) 6 (0.8) 2 (0.2) .28
Additional local procedures 278 (19.7) 187 (26.5) 91 (12.9) <.001
Drainage 60 (4.2) 36 (5.1) 24 (3.4) .11
Debridement 218 (15.5) 151 (21.4) 67 (9.5) <.001
Minor amputations 352 (25.0) 194 (27.5) 158 (22.5) .03
Toe(s), ray(s) 254 (18.0) 140 (19.8) 114 (16.2) .08
Transmetatarsal 98 (7.0) 54 (7.7) 44 (6.3) .30
ABI measurement 0.84 6 0.17 0.83 6 0.13 .21
(0.75-0.90) (0.77-0.89)
ABI, Ankle-brachial index; DM, diabetes mellitus; MI, myocardial infarction; nDM, no diabetes mellitus; PTFE, polytetraﬂuoroethylene; SD, standard
deviation.
Continuous data are presented as mean ± standard deviation (range) and categoric data as number (%).
Fig 1. Kaplan-Meier life-table analysis of primary patency rates for diabetesmellitus (DM) and no diabetesmellitus (nDM)
patients (odds ratio [OR], 1.20; 95% conﬁdence interval [CI], 0.97-1.52; log-rank test, P ¼ .09), for DM and nDM
patients using vein graft (OR, 1.19; 95% CI, 0.94-1.54; log-rank test, P ¼ .13) or polytetraﬂuoroethylene (PTFE) graft
(OR, 1.03; 95%CI, 0.60-1.77; log-rank test,P¼ .89).Rawnumber of the limbs at risk and the standard error (SE) analyzed
for each interval are shown for each subgroup. The SE exceeds 10% after 4 years only in the nDMgroup using PTFE graft.
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Fig 2. Kaplan-Meier life-table analysis of assisted primary patency rates for diabetes mellitus (DM) and no diabetes
mellitus (nDM) patients (odds ratio [OR], 1.06, 95% conﬁdence interval [CI], 0.83-1.36; log-rank test, P ¼ .60), for
DM and nDM patients using vein graft (OR, 1.07; 95% CI, 0.82-1.40; log-rank test, P ¼ .57) or polytetraﬂuoro-
ethylene (PTFE) graft (OR, 0.83, 95% CI, 0.44-1.54; log-rank test, P ¼ .56). Raw number of the limbs at risk and the
standard error (SE) analyzed for each interval are shown for each subgroup. The SE exceeds 10% after 4 years in the
DM and nDM groups using PTFE graft.
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similar for the diabetic and nondiabetic patients (65% and
46% vs 69.5% and 57%; log-rank test, P ¼ .09), whatever
the type of conduit used (Fig 1). The 5- and 10-year assis-
ted primary patency rates were 72% and 53% for the dia-
betics and 74% and 60% for the nondiabetics (log-rank
test, P ¼ .60), with no signiﬁcant difference between the
groups even after stratifying patients by conduit (Fig 2).
All the lesions involved were detected on duplex imaging
and were usually intrinsic defects distributed along the
length of the failing but still patent graft. Graft revisions
mainly involved thrombectomy and/or lysis, percutaneous
vein graft dilation, and patch angioplasty. At 5 and 10 years,
the secondary patency rates were comparable (76% and
60% in the diabetics vs 80% and 68% in the others; log-
rank test, P ¼ .20), regardless of the type of conduit
(Fig 3). In most of the failed grafts, the failure was due
to outﬂow or inﬂow disease secondary to myointimal
proliferation and hyperplasia or the progression of athero-
sclerotic lesions. Graft patency was restored with throm-
bectomy/lysis, until a satisfactory runoff was observed,
and a distal extension of the revascularization with
a “jump” vein graft in cases of outﬂow disease, or revision(proximal graft extension) in the cases of inﬂow disease.
Some failed IARs required operative revision only (throm-
bectomy) or thrombolytic therapy with urokinase, pro-
viding there was no underlying anatomic defect or no
atherosclerotic disease adjacent to the graft responsible
for graft failure, which was presumably related to a decrease
in blood ﬂow in a poor runoff bed. Overall, 109 major
amputations were performed (23% of them during the peri-
operative period) with no signiﬁcant differences between
the diabetic and nondiabetic groups (8.4% vs 7.5%; P ¼
.53) and the use of vein (8.3% vs 7.4%; P ¼ .60) or
PTFE conduits (9.2% vs 8.9%; P ¼ .95). No major ampu-
tation was necessary during the follow-up of above-the-
knee IARs. Twenty-one (19.2%) major amputations (18
in diabetic patients and 3 in nondiabetic patients; P ¼
.003) were needed because of persistent foot infections
and/or osteomyelitis despite a patent graft and occurred
between 8 and 18 months after surgery. At 5 and 10 years,
the limb salvage rates were 88% and 76%, respectively, in
the diabetic patients, 91% and 83% in nondiabetic patients
(log-rank test, P ¼ .12), and no signiﬁcant difference
emerged after stratifying patients by type of conduit
(Fig 4). The 5- and 10-year survival rates were 51% and
Fig 3. Kaplan-Meier life-table analysis of secondary patency rates for diabetes mellitus (DM) and no diabetes mellitus
(nDM) patients (odds ratio [OR], 1.18; 95% conﬁdence interval [CI], 0.91-1.56; log-rank test, P ¼ .20), for DM and
nDM patients using vein graft (OR, 1.19; 95% CI, 0.89-1.60; log-rank test, P ¼ .23) or polytetraﬂuoroethylene (PTFE)
graft (OR, 0.96; 95% CI, 0.47-1.95; log-rank test, P¼ .91). Raw number of the limbs at risk and the standard error (SE)
analyzed for each interval are shown for each subgroup. The SE exceeds 10% after 4 years only in the DM group using
PTFE graft.
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in the nondiabetic group (log-rank test, P ¼ .41; Fig 5).
The main known cause of death in both groups was cardiac
disease.
At 5 and 10 years, the amputation-free survival rates
were 45.5% and 27%, respectively, for the diabetics, and
51% and 29% for the nondiabetics (log-rank test, P ¼
.19; Fig. 6). On univariate analysis, considering all prog-
nostic variablesdage, sex, smoking, hypertension, hyper-
lipidemia, cardiac disease, CKD, prior MI or cardiac
surgery, prior stroke or inﬂow procedures, inﬂow source
and target outﬂow vessel, and type of conduitdas potential
predictors of revascularization failure or limb loss, none of
these variables inﬂuenced the outcome in either group.
DISCUSSION
Clinical and epidemiologic studies have found DM an
important risk factor for PAD,2 and patients with PAD
often have cerebrovascular or coronary artery diseases
that account for their poor prognosis and lower life expec-
tancy compared with the general population.27,28 PAD also
carries a strong risk of major lower extremity amputation in
diabetic people.29 CLI is the most severe stage of overt
PAD, and diabetic patients with CLI might be expectedto have a worse long-term prognosis than their nondiabetic
counterparts.
Our present ﬁndings indicate that diabetics can
undergo IAR for CLI with technical and clinical outcomes
statistically no different from those seen in nondiabetic
patients, despite a signiﬁcantly higher risk of nonfatal peri-
operative complications. Our diabetic patients were signif-
icantly younger at the time of surgery and had a higher
incidence of cardiac disease, hypertension, hyperlipidemia,
and CKD than our nondiabetic patients, which is hardly
surprising given that hypertension and hyperlipidemia are
risk factors for metabolic syndrome, and CKD is often
a complication of DM.
Although cardiac disease was present in more than 50%
of our patients, with high rates of prior MI and PTA/stent-
ing or coronary artery bypass grafting, the overall incidence
of perioperative nonfatal MI was only 2.8%, and its higher
prevalence among diabetic patients was statistically insignif-
icant (3.4% vs 2.1%; P ¼ .14). The diabetic and nondiabetic
patients’ comparable rate of cardiac complications conﬁrms
other reports10,19,22 but contrasts with the higher perioper-
ative cardiac morbidity often encountered in diabetics5,11
and attributed to a higher incidence of subclinical coronary
artery disease that is sometimes clinically silent.11
Fig 4. Kaplan-Meier life-table analysis of limb salvage rates for diabetes mellitus (DM) and no diabetes mellitus (nDM)
patients (odds ratio [OR], 1.32; 95% conﬁdence interval [CI], 0.91-1.96; log-rank test, P ¼ .12), for DM and nDM
patients using vein graft (OR, 1.38; 95% CI, 0.93-2.10; log-rank test, P ¼ .10) or polytetraﬂuoroethylene (PTFE) graft
(OR, 0.81; 95% CI, 0.26-2.48; log-rank test, P ¼ .71). Raw number of the limbs at risk and the standard error (SE)
analyzed for each interval are shown for each subgroup. The SE exceeds 10% after 4 years only in the nDM group using
PTFE graft.
Fig 5. Kaplan-Meier life-table analysis of survival rates for diabetes mellitus (DM) and no diabetes mellitus (nDM)
patients (odds ratio [OR], 1.08; 95% conﬁdence interval [CI], 0.88-1.33; log-rank test, P ¼ .41). Raw number of the
patients at risk and the standard error (SE) analyzed for each interval are shown for each subgroup.
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Fig 6. Kaplan-Meier life-table analysis of amputation-free survival rates for diabetes mellitus (DM) and no diabetes
mellitus (nDM) patients (odds ratio [OR], 1.12, 95% conﬁdence interval [CI], 0.94-1.35; log-rank test, P ¼ .19). Raw
number of the patients at risk and the standard error (SE) analyzed for each interval are shown for each subgroup.
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already reported in our recently published study in which
severe claudication and CLI were indications for IAR30),
whereas others have reported perioperative mortality rates
of 0.9% to 7%, usually with no difference between diabetic
and nondiabetic groups3,15,19-22 (Table IV). We have no
objective data to explain our remarkable results in terms
of a low perioperative cardiac morbidity and no deaths;
they may be due to our recognition of the patterns of
cardiac disease in diabetic patients and particularly the
higher incidence of silent coronary ischemia31 and higher
likelihood of congestive heart failure in such patients,32
prompting the use of lower cardiac stress testing thresholds
and an aggressive approach to invasive perioperative cardiac
monitoring.33 Our nil perioperative mortality is compa-
rable with the 0.9% 30-day mortality rate reported in a con-
secutive series of 795 infrapopliteal revascularizations
performed for CLI in diabetic patients,20 and other authors
reported the same 0.9% in their series of 228 pedal bypass
reconstructions for CLI in diabetic (n ¼ 170) and nondia-
betic patients (n ¼ 58).19
Although diabetic patients’ signiﬁcantly more advanced
disease at presentation might be expected to coincide with
worse technical outcomes, this was not true of our sample.
The diabetics fared just as well in IAR patency and limb
salvage rates as their nondiabetic counterparts, even after
stratifying by type of conduit. These ﬁndings correlate
well with other reports on the impact of DM on conven-
tional technical outcome measures9,10,15,17-23 but contrast
with worse patency rates and higher limb loss rates
recorded in diabetic patients5-8,11 attributable to a poor
infrageniculate runoff (a marker of more severe disease),
late surgery, and often broad tissue loss (especially withdeep infection), leading to major amputation despite
a patent revascularization.
Our intensive postoperative graft surveillance protocol
prompted many successful prophylactic lesion revisions,
explaining the marked improvement in patency rates for
failing and failed revascularizations at any time points in
both groups.
The incidence of limb loss was comparable in our dia-
betic and nondiabetic patients and is consistent with the
ﬁndings in most published series.9,10,15,17-23 The type of
conduit did not inﬂuence this outcome, probably because
prosthetic grafts were only used in about 10% of our
IARs. Considering that 80% of diabetic and 70% of nondi-
abetic patients had surgery for soft tissue loss, the two
groups’ comparable 5- and 10-year limb salvage rates
(88% and 76% in the diabetic group, 91% and 83% in the
nondiabetic group) clearly demonstrate the surgical proce-
dure’s efﬁcacy.
Contrasting with several reports6,8-11 but consistently
with others,20 we failed to conﬁrm any worse survival for
diabetic than for nondiabetic patients with CLI. In addi-
tion, the limited use of amputation-free survival as an
outcome measure in most recently published case series
or trials, makes it very hard to compare the rates of diabetic
and nondiabetic patients alive at 5 and 10 years with a func-
tional limb (46% and 27% vs 50% and 29%, respectively) in
the various experiences. Comparable amputation-free
survival rates between diabetic and nondiabetic patients
were reported in one prospective study on 44 diabetics
and 69 nondiabetics, although these patients underwent
combined arterial reconstruction and peripheral PTA, and
they were only followed for 12 months.22 Conversely,
a population-based cohort study comparing 742 diabetic
Table IV. Results of infrainguinal arterial reconstructions (IARs) in diabetic and nondiabetic patients in the recent
literature
Author BPG VG, % CLI, % 30-day death, % % PP, years % SP, years % LS, years % S, years % AFS, years
Karacagil9
DM 120 61 91 5 46 (3) NA 70 (3) 62 (3) NA
nDM 212 55 68 1.4 52 (3) NA 62 (3) 86 (3) NA
Wolﬂe10
DM 94 62 100 2 66 (1) 72 (1) 85 (1) 78 (1) NA
nDM 117 67 100 1 56 (1) 63 (1) 83 (1) 95 (1) NA
AhChong12
DM 176 66 100 4 46 (4) 57 (4) 78 (5) 33 (5) NA
nDM 89 63 100 1 34 (4) 47 (4) 81 (5) 43 (5) NA
Rutherford17
DM 104 56 85 NA 60 (3) NA NA NA NA
nDM 142 43 85 NA 42 (3) NA NA NA NA
Shah18
DM 387 100 74 NA 74 (5) NA 86 (5) NA NA
nDM 294 100 49 NA 76 (5) NA 94 (5) NA NA
Panneton19
DM 170 96 100 1.3 62 (5) 71 (5) 78 (5) 65 (5) NA
nDM 58 97 100 1.8 50 (5) 58 (5) 78 (5) 52 (5) NA
Akbari20
DM 795 91.6 93.7 0.9 75.6 (5) 77 (5) 87.3 (5) 58.1 (5) NA
nDM 167 88.6 82 4.2 71.9 (5) 73.6 (5) 85.4 (5) 58.0 (5) NA
Dorweiler21
DM 49 100 100 2 89 (4) NA 87 (4) NA NA
nDM 0
Awad22,a
DM 44 42 100 6.8 NA NA 78 (1) 93 (1) 71 (1)
nDM 69 42 100 7.2 NA NA 90 (1) 89 (1) 73 (1)
Present series
DM 705 88.5 100 0 46 (10) 60 (10) 76 (10) 34 (10) 27 (10)
nDM 702 86.8 100 0 57 (10) 68 (10) 83 (10) 38 (10) 29 (10)
AFS, Amputation-free survival; BPG, bypass grafting; CLI, critical limb ischemia; DM, diabetes mellitus; LS, limb salvage; NA, not available; nDM, no diabetes
mellitus; PP, primary patency; S, survival; SP, secondary patency; VG, vein graft.
aIn this study, peripheral revascularizations include arterial reconstructions and endovascular procedures.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 3 Ballotta et al 717and 1098 nondiabetic patients who underwent leg bypass
surgery for CLI found the diabetic patients’ amputation-
free survival period was signiﬁcantly shorter than in nondi-
abetic patients (2.3 vs 3.4 years),8 a ﬁnding consistent with
the overall amputation-free survival of the Bypass vs Angio-
plasty in Severe Ischaemia of the Leg (BASIL) trial (55% at
3 years)34 and of the Veterans Affairs National Surgical
Quality Improvement Program (57% at 3 years).6
Percutaneous treatments in the peripheral circulation,
especially for patients with CLI, have evolved in the last
5 years, and the outcomes have varied in the meantime.
A percutaneous approach may be less traumatic than tradi-
tional bypass surgery, but periprocedural complications and
1-year mortality rates continue to be high in many series,
particularly in the elderly population with distal arterial
involvement. We reserve an aggressive approach in such
patients, making an effort to the arterial reconstruction in
any CLI patients showing an inclination to walk again,
whenever their leg can be saved and the patient’s general
conditions allow for surgery. Endovascular procedures
should always be attempted before any primary amputation
(even though it is likely to be unsuccessful) in patients with
multiple comorbidities whose life expectancy is poor, given
there is nothing to lose by trying.Limitations of the study. This study has several limi-
tations to mention. First, our analysis is naturally limited by
the fact that it was retrospective, even though our data
were collected prospectively. Second, some say that
analyzing results from only one institution is not very useful
because it can only represent the experience of the authors
reporting them. Our ﬁndings reﬂect a single surgeon’s
experience and, while this ensures a uniformity of surgical
technique, it does not mean that it is reproducible. Third,
for obvious reasons, this series did not include bedridden or
nonambulatory cases, the mentally impaired, or patients
whose life expectancy was less than a year. Patients with
ample soft tissue loss in the plantar region were also ruled
out because, judging from our experience, many such
patients ultimately have major amputation after distal revas-
cularization (usually despite a patent graft and regardless of
the type of conduit) because they repeatedly develop deep
infections that prevent the wound from healing completely
for months, or because minor surgical revisions on more
proximal parts of their feet make it difﬁcult for them to
walk. This selection bias may skew our results because, if
we had considered such patients in our analysis, clinical
events not associated with the arterial reconstruction per
se would probably have inﬂuenced our data and our
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study may have considered a relatively selected patient
cohort rather than a sample of the general population of
CLI patients (with or without DM) also because the physi-
cians who refer cases to our institution (a tertiary care
center with a scientiﬁc interest and expertise in CLI
management) for revascularization, probably already
choose patients with a longer life expectancy, offering
a conservative management instead (that ultimately leads
to a major amputation) to patients with numerous comor-
bidities and poor general health. Other aspects that may
have contributed to our patients’ favorable outcome
include the use of regional anesthesia (epidural or spinal
anesthesia were used in all cases, limiting the risk of adverse
postoperative events) and a relatively quick surgical
procedure.
CONCLUSIONS
Judging from the results of the present study, diabetic
patients undergoing IAR for CLI can have the same 5- and
10-year survival and amputation-free survival rates as their
nondiabetic counterparts. The comparable technical and
clinical outcomes reported here strongly demonstrate that
diabetic patients with CLI can expect the same quantity
and quality of life as other patients with CLI, and aggres-
sive attempts at limb salvage in patients with DM,
including distal and foot level bypass grafting, should not
be discouraged.
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